BlueLinx - BXC Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BlueLinx in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BXC shares.
View BXC analyst ratings or view top-rated stocks.

5 equities research analysts have issued twelve-month price objectives for BlueLinx's shares. Their BXC share price forecasts range from $75.00 to $127.00. On average, they anticipate the company's stock price to reach $104.75 in the next twelve months. This suggests a possible upside of 64.6% from the stock's current price.
View analysts price targets for BXC or view top-rated stocks among Wall Street analysts.

BlueLinx's stock was trading at $95.76 at the beginning of the year. Since then, BXC stock has decreased by 33.5% and is now trading at $63.65.
View the best growth stocks for 2022 here.

BlueLinx saw a increase in short interest in the month of August. As of August 15th, there was short interest totaling 470,800 shares, an increase of 5.5% from the July 31st total of 446,100 shares. Based on an average trading volume of 168,200 shares, the days-to-cover ratio is presently 2.8 days. Currently, 5.2% of the company's stock are sold short.
View BlueLinx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our BXC earnings forecast.

BlueLinx Holdings Inc. (NYSE:BXC) announced its earnings results on Tuesday, August, 2nd. The construction company reported $7.48 earnings per share for the quarter, missing analysts' consensus estimates of $7.64 by $0.16. BlueLinx had a trailing twelve-month return on equity of 79.52% and a net margin of 7.26%. During the same quarter in the prior year, the firm posted $11.61 EPS.

56 employees have rated BlueLinx Chief Executive Officer Mitch Lewis on Glassdoor.com. Mitch Lewis has an approval rating of 49% among the company's employees. This puts Mitch Lewis in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other BlueLinx investors own include Novavax (NVAX), Micron Technology (MU), Co-Diagnostics (CODX), Livongo Health (LVGO), Intel (INTC), Maxar Technologies (MAXR), Civeo (CVEO), Nautilus (NLS), Sorrento Therapeutics (SRNE) and Hologic (HOLX).

BlueLinx trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXC."

Shares of BXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BXC stock can currently be purchased for approximately $63.65.

BlueLinx (NYSE:BXC) has a market capitalization of $614.86 million and generates $4.28 billion in revenue each year. The construction company earns $296.13 million in net income (profit) each year or $32.71 on an earnings per share basis.

The company employs 2,055 workers across the globe.

BlueLinx's mailing address is 1950 SPECTRUM CIRCLE SUITE 300, MARIETTA GA, 30067. The official website for the company is www.bluelinxco.com. The construction company can be reached via phone at (770) 953-7000, via email at ir@audentestx.com, or via fax at 770-221-8902.